This publication constitutes an analysis from the FRESCO-2 study2 and evaluates the health-related quality of life (HRQoL) impact of Fruzaqla® in patients with heavily pretreated metastatic colorectal cancer. The analysis concluded that Fruzaqla® did not negatively impact HRQoL while also extending survival.
- Time to Deterioration (TTD): Median TTD to ECOG Performance Status ≥ 2 or death was significantly longer in the Fruzaqla® group, highlighting its potential to maintain patient performance status over time.
- Performance Status: Fruzaqla® demonstrated a delay in the time to deterioration of ECOG performance status compared to placebo, indicating a slower decline in physical functioning.
- Safety Profile: Fruzaqla® extended survival while maintaining a favorable safety profile with manageable adverse events.
- Impact on Health-Related QoL: Fruzaqla® did not negatively impact HRQoL compared to placebo, making it a viable treatment option without compromising the quality of life for patients.
- Dasari A, Lonardi S,et al; FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15. PMID: 37331369.
- Fruzaqla® Swiss prescribing information at www.swissmedicinfo.ch.
- Sobrero A, Dasari A, et al. Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study. Eur J Cancer. 2025 Mar 11;218:115268. doi: 10.1016/j.ejca.2025.115268. Epub 2025 Jan 29. PMID: 39952149.
Healthcare professionals may request a complete copy of the cited literature from the pharmaceutical company.
C-APROM/CH/FRZ/0024_05/25